19 studies found for:    AMG145 | Phase 3
Show Display Options
Rank Status Study
1 Completed Study of Low-Density Lipoprotein Cholesterol (LDL-C) Reduction Using Evolocumab (AMG 145) in Japanese Patients With Advanced Cardiovascular Risk
Condition: Hyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular Events
Interventions: Drug: Atorvastatin;   Biological: Evolocumab;   Other: Placebo to Evolocumab
2 Completed
Has Results
Study to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe or a Prefilled Autoinjector/Pen
Conditions: Primary Hypercholesterolemia;   Mixed Dyslipidemia
Interventions: Biological: Evolocumab Pre-filled Syringe;   Biological: Evolocumab AI/pen
3 Not yet recruiting Trial Assessing Evolocumab (AMG 145) Compared to LDL-C Apheresis in Subjects Receiving LDL-C Apheresis Prior to Study Enrollment
Condition: Hypercholesterolemia
Interventions: Biological: evolocumab (AMG 145);   Other: Low Density Lipoprotein Cholesterol (LDL-C) Apheresis
4 Active, not recruiting Trial Assessing Long Term USe of PCSK9 Inhibition in Subjects With Genetic LDL Disorders
Condition: Severe Familial Hypercholesterolemia
Intervention: Biological: Evolocumab (AMG145)
5 Completed
Has Results
Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities
Condition: Homozygous Familial Hypercholesterolemia
Interventions: Biological: Evolocumab;   Drug: Placebo
6 Completed A Randomized, Multi-center Clinical Study in Subjects With Hypercholesterolemia or Mixed Dyslipidemia
Conditions: Primary Hypercholesterolemia;   Mixed Dyslipidemia
Intervention: Biological: evolocumab (AMG 145)
7 Completed
Has Results
Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study
Condition: Hypercholesterolemia
Interventions: Biological: Evolocumab;   Biological: Placebo;   Drug: Atorvastatin;   Drug: Ezetimibe;   Other: Diet Only
8 Completed Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2
Condition: Hyperlipidemia
Interventions: Biological: Evolocumab (AMG 145);   Other: Placebo
9 Active, not recruiting GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound
Condition: Hypercholesterolemia
Interventions: Biological: Evolocumab (AMG 145);   Other: Placebo
10 Active, not recruiting Open Label Study of Long Term Evaluation Against LDL-C Trial-2
Condition: Hyperlipidemia and Mixed Dyslipidemia
Interventions: Biological: evolocumab (AMG 145) and standard of care;   Other: Standard of care
11 Completed LDL-C Assessment w/ PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2
Condition: Hyperlipidemia
Interventions: Biological: evolocumab (AMG 145);   Other: Ezetimibe;   Other: Placebo (administered subcutaneously);   Other: Placebo (administered orally);   Drug: Atorvastatin;   Drug: Rosuvastatin;   Drug: Simvastatin
12 Completed Effects on Lipoprotein Metabolism From PCSK9 Inhibition Utilizing a Monoclonal Antibody
Condition: Primary Hyperlipidemia and Mixed Dyslipidemia
Interventions: Biological: Evolocumab (AMG 145);   Drug: Atorvastatin;   Drug: Placebo
13 Enrolling by invitation Extension (OLE) Study to Assess Safety and Efficacy of Evolocumab
Condition: Hypercholesterolemia
Intervention: Biological: Evolocumab
14 Completed Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2
Condition: Hyperlipidemia
Interventions: Biological: Evolocumab (AMG 145);   Other: Placebo (administered subcutaneously);   Drug: Ezetimibe;   Other: Placebo (administered orally)
15 Completed Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2
Condition: Hyperlipidemia
Interventions: Biological: Evolocumab (AMG 145);   Drug: Ezetimibe;   Other: Placebo (administered subcutaneously);   Other: Placebo (administered orally)
16 Active, not recruiting Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Condition: Dyslipidemia
Interventions: Biological: Evolocumab (AMG 145);   Other: Placebo;   Drug: Effective statin therapy
17 Active, not recruiting Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects
Condition: Dyslipidemia
Interventions: Biological: Evolocumab (AMG 145);   Other: Placebo;   Drug: Effective statin therapy
18 Not yet recruiting Trial Assessing Efficacy, Safety and Tolerability of PCSK9 Inhibition in Paediatric Subjects With Genetic LDL Disorders
Condition: Heterozygous Familial Hypercholesterolemia
Interventions: Drug: Evolocumab;   Drug: Placebo
19 Active, not recruiting Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3
Condition: Hyperlipidemia
Interventions: Drug: Part A, Atorvastatin;   Other: Part A, Placebo (administered orally);   Drug: Part B, Evolocumab;   Other: Part B, Placebo (administered orally);   Drug: Part B, Ezetimibe;   Other: Part B, Placebo (administered subcutaneously);   Drug: Part C, Evolocumab

Indicates status has not been verified in more than two years